Fluorodeoxyglucose Imaging Research Articles

Assessment of myocardial viability using F-18 fluorodeoxyglucose/Tc-99m sestamibi dual-isotope simultaneous acquisition SPECT: Comparison with Tl-201 stress-reinjection SPECT

This study compared technetium 99m sestamibi/fluorine 18 fluorodeoxyglucose dual-isotope simultaneous acquisition (DISA) with stress-reinjection thallium 201 single photon emission computed tomography (SPECT) with regard to their ability to detect myocardial viability. The study cohort consisted of 42 angiographically significant coronary artery disease patients with symptomatic congestive heart failure or regional wall motion abnormalities. In total, 398 dysfunctional segments in 40 patients were analyzed (2 patients were excluded because of poor-quality F-18 fluorodeoxyglucose images). Of the segments, 217 were diagnosed as viable and 144 as nonviable by both DISA and Tl-201, 33 were viable by DISA but nonviable by Tl-201, and 4 were viable by Tl-201 but nonviable by DISA. Most discrepancies were in the inferior wall. Of the 40 patients, 16 underwent revascularization. From the follow-up results for the 105 dysfunctional segments in these 16 patients, DISA viability appears to be a significant predicting factor (P = .014) for functional recovery after revascularization statistically whereas Tl-201 viability does not (P = .09). Our study suggests that DISA viability provides more accurate prediction of postrevascularization functional recovery than Tl-201 viability. Given the small number of patients who underwent revascularization, the superiority of DISA over Tl-201 in detecting myocardial viability may be firmly established by further study on a large scale for patients with profound left ventricular dysfunction.

Biodistribution and Imaging of FDG in Rats with LS174T Carcinoma Xenografts and Focal Escherichia coli Infection

The aim of this study was to compare the dynamic distribution of fluorodeoxyglucose (FDG) in malignant and in infectious lesions. The dynamic distribution of FDG was studied in Rowett nude (RNU) rats with a LS174T carcinoma xenograft in the left front leg and an Escherichia coli-induced focal infection in the right front leg. In 5 rats, dynamic FDG-PET was performed (27 frames of 6-15 minutes) up to 4 hours after injection of 11 MBq 18FDG. The mean FDG uptake (SUV) was calculated and plotted by using a region of interest (ROI) centered over both lesions. In groups of 6 rats, the biodistribution of FDG was determined by counting dissected tissues at 1, 2, 3, and 4 hours after an injection of 11 MBq FDG. Means +/- the standard error of the mean (SEM) were calculated. Dynamic positron emission tomography (PET) visualized both the tumor and the infection. The ROI analysis showed that FDG uptake in the infections was faster and higher, as compared to the tumor lesions. FDG uptake in the tumor reached a standardized uptake value (SUV) of 0.8 +/- 0.3 at 60 minutes and in the infectious lesions a SUV of 1.6 +/- 0.2 at 45 minutes, both remaining constant until 4 hours postinjection (p.i.). In the biodistribution study with ex vivo tissue counting, FDG had accumulated up to 1.1 +/- 0.1 %ID/g and 0.8 +/- 0.1 %ID/g at 1 hour in the tumor and infection, respectively, and remained constant until 4 hours for both lesions without significantly different wash-out from the 2 lesions. The tumor/blood and abscess/ blood ratios increased with time to 57 +/- 17 and 48 +/- 14, respectively. Although in this model differences in absolute FDG uptake and initial kinetics between tumor and infection were observed, the wash-out rate of FDG from the lesions was similar over time. The retention of FDG in the inflammatory lesion indicated that dual time-point imaging does not necessarily resolve diagnostic pitfalls for FDG-PET in oncology in order to discriminate between malignant tumorous and benign infectious lesions.

Seeing into cells. The promise of in vivo molecular imaging in oncology.

Medicine is undergoing a revolution. Disease is increasingly being redefined in terms of underlying molecular abnormalities, as opposed to the signs and symptoms of the patient. This new definition is referred to as the ‘molecular signature’ of a disease and the current developments in biomedical research are accordingly termed ‘molecular medicine’. In the case of cancer, we know that tumours result from genetic alterations of cells, which may involve overexpression or underexpression of normal genes, or mutations that generate abnormal gene products. This may affect any of the molecules within the cell, the cell membrane or the cancer‐cell milieu. In addition, the microenvironment of a tumour, including stromal and vascular endothelial cells, is important for the growth and persistence of the tumour. This entire constellation of the abnormal molecular biology of tumour cells and their microenvironment is the molecular signature of cancer (Hanahan & Weinberg, 2000). > The greatest potential value of molecular imaging is its ability to report on the molecular state of a tumour in its normal milieu One consequence of this new understanding of disease is the increased effort to develop targeted drugs that interact specifically with the altered genes or their products and either limit the progression of or kill tumour cells. The hope is that such therapeutics will selectively target tumour cells and leave normal cells untouched, thereby reducing the common side effects of current anticancer therapies such as radio‐ and chemotherapy. There is an increasing number of such targeted therapeutics being developed and made available for clinical use. For example, until about five years ago, there were few options available for treating colon cancer beyond surgically removing the affected part of the colon and using standard chemotherapy. However, since 1999, the US Food and Drug Administration (FDA) has approved at least five targeted drugs …

The role of 18F fluorodeoxyglucose triple-head coincidence imaging in the diagnosis of suspected lung cancer

To evaluate the accuracy of [18F] fluorodeoxyglucose (FDG) triple-head coincidence imaging in the setting of suspected lung cancer. 109 patients with suspected lung cancer were enrolled in the present study. According to the diameter of the lesion (> 1.5 cm, </= 1.5 cm), patients were divided into two groups. The sensitivity, specificity and accuracy of the results were calculated and the results were compared with pathological results. Of the total of 109 patients, 86 cases were confirmed as lung cancer whereas 23 cases were benign by pathological study. The sensitivity, specificity and accuracy of FDG imaging were 95% (82/86), 74% (17/23) and 91% (99/109), respectively. For the group of lesion diameter > 1.5 cm, the sensitivity, specificity and accuracy were 98% (81/83)), 63% (10/16) and 92% (91/99), respectively. While for the group of lesion diameter </= 1.5 cm, the results were 1/3, 7/7, and 8/10, respectively. The difference between the two groups was significant (P = 0.005). The technique of [18F] FDG imaging is an useful method for routine evaluation of patients with suspected lung cancer. The sensitivity of detection is related to lesion size, if lesions </= 1.5 cm in diameter the results of FDG imaging should be carefully analyzed.

Peritoneal Carcinomatosis From Cervical Cancer Detected by F-18 FDG Positron Emission Tomography

A 41-year-old woman with a history of rheumatoid arthritis and newly diagnosed cervical carcinoma was treated with cisplatin and whole-pelvis radiotherapy with minimal response. Computed tomographic scan of the abdomen and pelvis at the time of diagnosis demonstrated no evidence of extrapelvic disease. She underwent F-18 fluorodeoxyglucose (FDG-PET) imaging to evaluate for extrapelvic extension of disease for consideration of total pelvic exenteration. Coronal and axial reconstructed images revealed a large pelvic mass with evidence of diffuse FDG uptake along the peritoneal surfaces of the abdomen and pelvis, consistent with diffuse peritoneal implants. Subsequent diagnostic laparoscopy demonstrated a large omental cake with diffuse carcinomatosis, biopsy positive for metastatic squamous cell carcinoma, and a small amount ofascites. The patient declined further treatment and died of her disease approximately one month later.

Added value of attenuation-corrected Tc-99m tetrofosmin SPECT for the detection of myocardial viability: Comparison with FDG SPECT

The aim of this study was to evaluate the value of attenuation correction of technetium 99m tetrofosmin single photon emission computed tomography (SPECT) imaging for the detection of myocardial viability. A head-to-head comparison between resting Tc-99m tetrofosmin SPECT and fluorine 18 fluorodeoxyglucose (FDG) SPECT was performed. Both the noncorrected and attenuation-corrected Tc-99m tetrofosmin SPECT images were compared with the FDG images that served as the reference for viability. Consecutive patients (n = 33) with chronic coronary artery disease and left ventricular dysfunction were included. Segmental Tc-99m tetrofosmin and FDG data were displayed in polar maps (17-segment model), and the segments were normalized to peak activity by use of the 4D-MSPECT software program. Segments with normalized FDG activity greater than 50% were considered viable. A similar cutoff value to assess viability was used for the noncorrected and attenuation-corrected Tc-99m tetrofosmin images. Regional contractile function was determined from the gated Tc-99m tetrofosmin images and scored as normokinesia, hypokinesia, or akinesia/dyskinesia. Of all segments, 482 (85%) were viable on FDG SPECT. Of these, 427 (89%) were classified as viable with noncorrected Tc-99m tetrofosmin. Thus 55 (11%) were underestimated with noncorrected Tc-99m tetrofosmin SPECT; these segments were mainly located in the inferior and inferoseptal regions. Attenuation correction changed the classification of 39 (70%) of the underestimated segments to viable. By use of attenuation correction, the agreement between Tc-99m tetrofosmin and FDG imaging improved from 84% to 90%. Similar observations were made when the analysis was restricted to the dysfunctional segments. The addition of attenuation correction to Tc-99m tetrofosmin SPECT significantly improved detection of myocardial viability in patients with chronic coronary artery disease, although minimal underestimation of viability remained as compared with FDG SPECT imaging.

MEASUREMENTS OF OCCUPATIONAL EXPOSURE FOR A TECHNOLOGIST PERFORMING 18F FDG PET SCANS

Radiation doses to one PET technologist performing 100 18F FDG (18F fluorodeoxyglucose) imaging procedures were measured in a clinical setting using two types of thermoluminescent dosimeter (TLD) badges, one finger-ring TLD and one electronic pocket dosimeter (EPD). 18F FDG was handled either with unshielded or with viewing window tungsten shielded syringes. The resulting doses using unshielded syringes were 13.8 +/- 0.8 microSv/370 MBq and 14.3 +/- 0.4 microSv/370 MBq, measured with TLD 100 and with TLD 700H/600H, respectively. For the same series of measurements, the doses obtained using shielded syringes were 10.7 +/- 0.4 microSv/370 MBq and 7.2 +/- 2.1 microSv/370 MBq with TLD700H/600H and with EPD, respectively. The dose to the right hand from shielded syringes was 69.3 +/- 5.5 microSv/370 MBq. All these values are within the ICRP recommended dose limits. Extrapolated to 725 examinations per year, the resulting effective dose measured with TLD would be 10 mSv with unshielded and 7.5 mSv with shielded syringes, respectively (25% dose reduction). The doses measured by TLD were consistently higher than those measured by EPD, suggesting that EPD measurements might underestimate occupational doses.

Influence of ceftriaxone treatment on fdg uptake—an in vivo [ 18f]-fluorodeoxyglucose imaging study in soft tissue infections in rats

Our aim was to determine the influence of antibiotic treatment using ceftriaxone on [ 18F]-fluorodeoxyglucose (FDG) uptake in experimental soft tissue infections. PET scans were performed in two groups (treated n=4; non-treated n=4) at days 3, 5, and 6 after inoculation of the infection. Additional autoradiography was performed in four animals at day 7 and in three animals at day 11. The difference of FDG uptake on day 5 (after three days of antibiotic treatment) between both groups proved to be significant ( df=6; T=2.52; p=0.045). FDG uptake determined at the other days did not reveal significant difference between the two groups. It seems to be possible that the effect of antibiotic treatment on FDG uptake is less evident than reported for therapy monitoring of cancer treatment. The change of FDG uptake over time in treated and untreated infections is complex and further in vivo experiments have to be initiated to investigate the potential value of clinical FDG PET in therapy monitoring of infection.

Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography—clinical use, interpretation methods, diagnostic improvements

Positron emission tomography (PET)/computed tomography (CT) scanners with combined dedicated high performance PET and CT scanners have been introduced recently in PET imaging. Oncological imaging with fluorodeoxyglucose (FDG) is currently the dominant application of PET. The addition of CT to PET offers many advantages, including obtaining a fast and relatively low-noise transmission scan, shortening the duration of the examination, adding precise anatomical information to FDG imaging, and providing additional diagnostic information. However, the use of CT for attenuation correction can lead to some artifacts that need to be considered when interpreting a PET/CT study: quantitative measurements may be altered, high density IV and oral and metallic objects may produce artifacts, and the registration of PET and CT may occasionally be suboptimal. Areas where using PET/CT offers particular potential advantages include the head and neck region, abdomen, and pelvis. Even in the thorax, PET/CT offers some advantages. Although clinical data evaluating the added value of PET/CT over PET are presently limited, preliminary results are very encouraging. More studies are warranted to clearly define the clinical impact of PET/CT over PET; however, it is clear this dedicated fusion technology will be very important for patient imaging in the coming years. © 2003 Elsevier Inc. All rights reserved.

Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma.

Until recently, gallium-67 scintigraphy (GS) has been the best available functional imaging modality for evaluating patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). The diagnostic accuracy of GS in detecting lymphoma is based on optimisation of the imaging protocol, knowledge of potential physiological and benign sites of (67)Ga uptake, and the Ga avidity characteristics of the individual lymphoma. As (67)Ga is a tumour viability agent, the role of GS is primarily at follow-up. A residual mass persisting on CT after treatment poses a common clinical dilemma: it may indicate the presence of viable lymphoma, which requires further treatment, or it can be benign, consisting of only fibrotic and necrotic tissues. GS can successfully differentiate between these conditions. Routine follow-up with GS may allow early diagnosis of recurrence and early institution of treatment. Reversion of a positive GS to a negative test, and the rapidity with which this occurs has a high predictive value for the outcome of the individual patient. Lymphoma showing a normal GS early during treatment has a better prognosis than lymphoma with persistence of pathological findings. Other tumour-seeking single-photon emitting agents, such as thallium-201, technetium-99m methoxyisobutylisonitrile and indium-111 octreotide, have been investigated in lymphoma, primarily as an alternative to GS in specific clinical settings, but are of limited value. The role of radioimmunoscintigraphy is gaining importance in conjunction with radioimmunotherapy. Fluorine-18 fluorodeoxyglucose (FDG) imaging of lymphoma using either dedicated or camera-based PET systems is gradually replacing GS for assessment of lymphoma. FDG overcomes some of the limitations of GS while sharing its tumour viability characteristics. The extensive clinical knowledge and experience accumulated over three decades with GS in lymphoma provides a solid background as well as a model for the assessment of new functional imaging techniques.

The Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging in the Evaluation of Hepatocellular Carcinoma

It has been well established that hepatocellular carcinomas (HCCs) accumulate [18F]fluorodeoxy-glucose (FDG) to varying degrees; this is thought to be due to differing amounts of FDG-6-phosphatase activity. The purpose of this study was to evaluate the impact of FDG imaging on the management of patients diagnosed with hepatocellular carcinoma. We conducted a retrospective review of the clinical data of 91 consecutive patients diagnosed with HCC who underwent FDG-positron emission tomography (PET) imaging between August 1993 and March 2001. The patients were divided into two groups. In Group one 67 of 91 (74%) patients were evaluated for proven but untreated hepatic lesions using PET. In Group two the remaining 24 patients (26%) were referred for evaluation of HCC recurrence but did not have prior PET. The FDG images were acquired with two dedicated PET tomographs [Siemens ECAT 933, CTI (Knoxville, TN) and GE Advance, General Electric Medical Systems (Milwaukee, WI)] one hour after the intravenous administration of 10 mCi of FDG. Tumor biopsy or resection specimens were available for review from 34 patients and were evaluated for histologic grade, presence of cirrhosis, tumor necrosis, and intratumoral fibrosis. In group one 43 of 67 (64%) of the HCCs accumulated FDG. Sixteen of the 43 patients in whom FDG was accumulated had multiple subsequent FDG-PET scans either for monitoring therapy or for detection of recurrence. FDG-PET imaging had an impact on the management of 20 of these patients: by guiding the biopsy at the metabolically active site of a large necrotic tumor (one), by identifying distant metastases (five), by monitoring the response to treatment with hepatic chemoembolization and guiding additional regional therapy (12), and by detecting recurrence (two). In group two recurrence and/or metastases were demonstrated with FDG-PET imaging in six of 24 (25%) patients, three of whom had multiple subsequent FDG-PET scans to monitor their treatment. Higher histopathologic grade and intratumoral fibrosis but not necrosis or cirrhosis correlated with PET positivity. In this study only 64 per cent of HCCs accumulated FDG. Despite this limitation FDG-PET imaging remains a useful tool in the diagnosis and treatment of HCC. FDG-PET imaging had a clinically significant impact in 26 of 91 (28%) patients with HCC. This includes detection of unsuspected metastatic disease in high-risk patients—including liver transplant candidates—and monitoring response to hepatic-directed therapy. FDG-PET should be considered as part of the workup and management of selected patients with HCC.

FDG-PET Findings in the Wernicke-Korsakoff Syndrome

This study reports FDG-PET findings in Wernicke-Korsakoff patients. Twelve patients suffering amnesia arising from the Korsakoff syndrome were compared with 10 control subjects without alcohol-related disability. Subjects received [ 18F]-fluorodeoxyglucose (FDG-PET) imaging as well as neuropsychological assessment and high-resolution MR imaging with volumetric analysis. Volumetric MRI analysis had revealed thalamic and mamillary body atrophy in the patient group as well as frontal lobe atrophy with relative sparing of medial temporal lobe structures. Differences in regional metabolism were identified using complementary region of interest (ROI) and statistical parametric mapping (SPM) approaches employing either absolute methods or a reference region approach to increase statistical power. In general, we found relative hypermetabolism in white matter and hypometabolism in subcortical grey matter in Korsakoff patients. When FDG uptake ratios were examined with occipital lobe metabolism as covariate reference region, Korsakoff patients showed widespread bilateral white matter hypermetabolism on both SPM and ROI analysis. When white matter metabolism was the reference covariate, Korsakoff patients showed relative hypometabolism in the diencephalic grey matter, consistent with their known underlying neuropathology, and medial temporal and retrosplenial hypometabolism, interpreted as secondary metabolic effects within the diencephalic-limbic memory circuits. There was also evidence of a variable degree of more general frontotemporal neocortical hypometabolism on some, but not all, analyses.

Fluorodeoxyglucose imaging using a coincidence gamma camera to detect head and neck squamous cell carcinoma and response to chemotherapy.

This prospective study was performed to evaluate the ability of a dual-head gamma camera with fluorine-18 fluorodeoxyglucose coincidence detection emission tomography (FDG-CDET) to detect primary tumor and cervical lymph nodes in head and neck squamous cell carcinoma (HNSCC), and to show the response of the carcinoma to chemotherapy. The findings were compared with those of physical examination, computed tomography (CT), and histopathology, before treatment in 61 patients, and after induction chemotherapy in 34 of them. Before treatment, the primary was detected in 93%, 79%, and 95% of cases on panendoscopy, CT, and FDG-CDET, respectively. After chemotherapy, 34 patients were evaluable for response of the primary tumor. Surgical resection was performed in 23 of them: agreement with histopathologic results for response to treatment was 74%, 69%, and 78% for panendoscopy, CT, and FDG-CDET, respectively. No surgical resection was performed in 11 of the 34 patients, but biopsies were performed before radiotherapy, and their rates of agreement with histopathologic results for response to treatment were 75%, 75%, and 67% on panendoscopy, CT, and FDG-CDET, respectively. For cervical lymph nodes, 245 sites were resected in 41 patients, and FDG-CDET appeared competitive with CT in detecting metastatic neck disease, especially after neoadjuvant chemotherapy; the accuracy was 93%. These results demonstrated the ability of FDG-CDET to detect primary tumors and cervical lymph nodes in HNSCC and to show its response to chemotherapy, as compared to the ability of CT and panendoscopy. It may be a complementary tool to evaluate residual disease after induction chemotherapy, although higher sensitivity would be required for FDG-CDET to be considered as a staging modality.

PET imaging using a triple-head gamma camera.

Interest in clinical fluorodeoxyglucose (FDG) imaging with multiple-head gamma cameras is growing. To improve sensitivity, triple-head coincidence imaging has been proposed. We report our initial experiences with a triple-head coincidence gamma camera with 19 mm sodium iodide crystal thickness. Several positron emission tomography-image quality parameters were evaluated using a Carlson and line source phantom. The system sensitivity with two-dimensional axial shields was 830 cps kBq-1 ml-1 and maximum noise equivalent count rate 1900 cps for an 18F-activity of 50 MBq. The imaging resolution was in central axial 7.0 mm and in central transaxial 7.6 mm, respectively. The average scatter fraction in scattered media was 29%. Clinical brain, heart and whole body images studies with [18F]FDG were acquired and they show good correlation with the phantom image quality. As a conclusion, triple-head coincidence gamma camera provides relatively high-count rate imaging with good contrast and resolution.

Role of nuclear medicine in diagnosis of the infected joint replacement.

Some complications of joint replacement surgery are easily diagnosed; however, differentiating infection from aseptic loosening is difficult because these entities are remarkably similar at clinical and histopathologic examination. Clinical signs and symptoms, laboratory tests, radiography, and joint aspiration are insensitive, nonspecific, or both. Cross-sectional imaging modalities are hampered by artifacts produced by the prosthetic devices themselves. Radionuclide imaging is not affected by the presence of metallic hardware and is therefore useful for evaluating the painful prosthesis. Bone scintigraphy is useful as a screening test, despite an accuracy of only 50%-70%, because normal results essentially exclude a prosthetic complication. The addition of gallium-67, a nonspecific inflammation-imaging agent, improves the accuracy of bone scintigraphy to 70%-80%. The accuracy of combined leukocyte-marrow imaging, 90%, is the highest among available radionuclide studies. Its success is due to the fact that leukocyte imaging is most sensitive for detection of neutrophil-mediated inflammation (ie, infection). The success of leukocyte-marrow imaging is tempered by the limitations of in vitro labeling. In vivo labeling has been investigated, and a murine monoclonal antigranulocyte antibody appears promising. Some investigations have focused on fluorodeoxyglucose imaging. Although this method is sensitive, specificity is a concern.

Mediastinal Lymph Node Sampling Following Positron Emission Tomography With Fluorodeoxyglucose Imaging in Lung Cancer Staging

To evaluate the predictive accuracy as well as the rates of false-positive and false-negative results of CT and positron emission tomography (PET)-fluorodeoxyglucose (FDG) imaging in detecting the metastatic intrathoracic lymph nodes in patients with suspected or proven non-small cell lung cancer (NSCLC). Our other objective was to determine the need for routine invasive sampling procedure in confirming PET/CT staging results. The results of CT and PET-FDG scanning in 77 patients with suspected or proven NSCLC were correlated with the histologic findings of hilar/mediastinal lymph node sampling using mediastinoscopy, open biopsy, thoracotomy, or thoracotomy with resection. Patients were then classified into resectable and unresectable groups based initially on PET results and compared to histologic findings. The sensitivity, specificity, and accuracy of CT and PET for detecting metastatic lymphadenopathy were 68%, 61%, 63%, and 87%, 91%, and 82%, respectively. A change of management with routine sampling following PET was seen in five of six patients (83%) with false-positive findings (13%) but in none of four patients (9%) with false-negative findings. The false-positive findings of PET-FDG imaging affected selection of treatment in 83% of patients. However, false-negative results did not change management in any patient. This could potentially prevent unnecessary invasive thoracotomy, mediastinoscopy, or other sampling procedures in patients with negative PET results.

Clinical Utility of PET-FDG Imaging in Differentiation of Benign from Malignant Adrenal Masses in Lung Cancer

This study was designed to evaluate the sensitivity, specificity, and predictive accuracy of PET-FDG imaging in detecting metastatic disease involvement of adrenal glands in patients with lung cancer. We wanted to compare efficacy of positron emission tomography (PET)-fluorodeoxyglucose (FDG) imaging to computed tomography (CT) scanning in differentiating benign from malignant involvement of adrenal glands in patients with lung cancer. Thirty patients with biopsy-proven lung cancer and abnormal findings on PET and/or CT scanning were studied for presence of adrenal abnormality suggestive of metastatic disease involvement (n = 26) or benign adrenal enlargement (n = 4). The results of PET and CT scanning were compared to histological findings and/or clinical follow-up for at least 1 year for presence or absence of adrenal metastases. PET-FDG imaging correctly detected the presence of metastatic involvement in 17 of 18 patients and excluded metastatic involvement in 11 of 12 patients for sensitivity, specificity, and accuracy of 94.4%, 91.6%, and 93.3%, respectively. CT scanning showed enlarged adrenals without metastases in 8 of 30 patients and normal-sized adrenals in the presence of metastases in 5 of 30 patients. There was a false-positive PET finding in 1 patient and a false-negative PET finding in another patient. PET-FDG imaging is a highly sensitive, specific, and accurate test to differentiate benign from malignant involvement of adrenal glands in patients with lung cancer and often ambiguous findings on CT scanning.

Treatment Outcome of Lung Cancer Patients as Optimized by Preoperative Whole-Body Positron Emission Tomography Fluorodeoxyglucose Imaging

Positron emission tomography (PET) fluorodeoxyglucose (FDG) imaging may be more accurate than computed tomography (CT) scanning for staging of lung cancer disease. In the present study, we evaluate whether whole-body PET-FDG imaging can accurately stratify lung cancer patients by stage and thus predict patient outcome. Forty-one consecutive patients underwent whole-body PET and CT scanning for preoperative staging, which was then confirmed by mediastinoscopy, thoracotomy, and/or other tests revealing distant metastases. The effect of PET on patient management was determined. PET was significantly more accurate than CT for staging of lung cancer (97.6% vs. 70.7%). One-year follow-up for survival rate and treatment response was also compared in different patient groups. PET accurately identified patients with resectable disease (Group A). Group B patients, with medically inoperable disease, and Group C patients, with unresectable advanced disease, had 100% and 53% incidence of adverse events (defined as recurrence, evidence of new disease, or death), respectively. Group A patients with resectable disease who underwent surgery showed the best patient outcome, with only 7% incidence of adverse events. In conclusion, whole-body PET can be useful in identifying a group of lung cancer patients with resectable disease most likely to benefit from surgical resection. Further studies are needed to explore whether PET can predict patient outcome of various lung cancer patients receiving different treatment regimens.

Commentary on “Treatment Outcome of Lung Cancer Patients as Optimized by Preoperative Whole-Body Positron Emission Tomography Fluorodeoxyglucose Imaging”

Commentary on “Treatment Outcome of Lung Cancer Patients as Optimized by Preoperative Whole-Body Positron Emission Tomography Fluorodeoxyglucose Imaging”

Muscle uptake of 18-fluorine fluorodeoxyglucose

F LUORODEOXYGLUCOSE (FDG) is well established as a tumor-seeking agent that is taken up by a wide variety of malignant tumors. Several nonmalignant lesions also are FDG avid, as are normal organ systems that use glucose as part of their metabolism. Low-grade FDG uptake in muscles is part of the normal biodistribution pattern of FDG, especially during physical activity. When this uptake is symmetric and corresponds to the location of a specific group of muscles, it is easily recognizable. Accurate interpretation of asymmetric muscular activity is more difficult. Recognition of unusual patterns and the location of benign physiologic muscular uptake of FDG is important for avoiding misinterpretations of positron emission tomography (PET) images. I describe 4 cases with unusual muscular FDG uptake that was noted during whole-body FDG imaging of nondiabetic patients. CASE 2